WEIGHT-BASED DOSING OF ENOXAPARIN AND ANTIFACTOR XA LEVELS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICALLY-ILL PATIENTS

Objective: The objective of the study was to evaluate peak antifactor Xa (aFXa) levels in low-weight patients receiving enoxaparin for VTE prophylaxis. Methods: Retrospective cohort adult weighing <55 kg who hospitalized at tertiary care Center between January 2019 through February 2020. All received prophylaxis with a aFXa level drawn. primary end point proportion achieving within goal range 0.2–0.5 units/ml. Results: Of 65 an appropriately timed level, 74% achieved and median daily dose 30 mg. mean weight about 44 kg. No significant correlations body mass index or were found. Conclusion: A lower may be reasonable There appears no safety concerns reduced dosing patients. More robust data are needed confirm these findings.